![]() ![]() As we increase Flagship's capital contribution to $60M, we welcome our new financial partners as long-term investors in Tessera’s mission of delivering on the full potential of genetic medicine.” ![]() “Tessera’s Gene Writing platform further expands the decade-long work done at Flagship Labs on new medicines based on nucleic acid codes-programmable therapeutic molecules such as messenger RNA, targeted fusogenic vectors and epigenetic controllers. “Tessera has pioneered an entirely new platform for curing diseases at their source: DNA,” said Noubar Afeyan, Chairman and Co-Founder of Tessera Therapeutics and Founder and CEO of Flagship Pioneering. “We look forward to turning this powerful technology into a new category of medicines.” Today’s support is a testament to Tessera’s outstanding team of scientists and our focus on bringing the extraordinary promise of Gene Writing to patients,” said Geoffrey von Maltzahn, CEO and Co-Founder of Tessera Therapeutics. The ability to write in the code of life will be a defining technology of this century and drive a fundamental change in medicine. “We are grateful to have support from world class investors in this funding round. By changing any base pair to another, making small insertions or deletions, and writing entire genes into the genome, Gene Writing unlocks the potential to cure genetic diseases and create life-changing therapeutics in cardiovascular, oncological, neurodegenerative, and infectious diseases. Tessera, unveiled in July 2020 after multiple years of in-house innovation within Flagship Labs, is pioneering Gene Writing-a new technology that has the ability to write therapeutic instructions into the genome to treat diseases at their source. The round was co-led by Alaska Permanent Fund Corporation, Altitude Life Science Ventures, and SoftBank Vision Fund 2 i, with participation from Qatar Investment Authority (QIA) and others. CAMBRIDGE, Mass.-( BUSINESS WIRE)-Tessera Therapeutics, an early-stage life sciences company founded by Flagship Pioneering, announced today that it has raised over $230M in Series B financing. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |